Exchange: NASDAQ·Updated 07:50 PM EDT
News
all
press releases
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
More News
Why Revolution Medicines May Be Big Pharma's Next Takeover Target
Why Revolution Medicines May Be Big Pharma's Next Takeover Target...
Yahoo! Finance: News
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including...
Business Wire
Here's How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.08% on an annualized basis producing an average annual return of 49.88%. Currently, Revolution Medicines has a marketread more...
Benzinga
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.
Zacks
Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?
Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story...
Yahoo! Finance: News
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?
Key PointsDruckenmiller initiated a new stake in Revolution Medicines in Q1...
Nasdaq News: Markets
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?
A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.
Stocktwits
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
Key PointsDruckenmiller bought 316,000 shares of Revolution Medicines in the first quarter...
Nasdaq News: Markets
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
Zacks

Advertisement|Remove ads.